Advertorial

Catalent expert invited to speak on the advantages of single use biomanufacturing for facility expansions

0
SHARES

Posted: 19 July 2012 | | No comments yet

Why single use is ideal for cell line development and bio-manufacturing…

Michael Jenkins, Ph.D., General Manager of Catalent Pharma Solutions Middleton, WI biologics facility, will present “The Need for Speed: Why Single Use is Ideal for Cell Line Development and Bio-Manufacturing” at the 2012 Bio-Process Systems Alliance (BPSA) International Single Use Summit on July 23-25, in Washington, DC.

 

Reserve your FREE place

 


Address the time-to-result challenge posed by short shelf-life radiopharmaceuticals.

20 November 2025 | 3:00 PM GMT | FREE Virtual Panel Discussion

This webinar showcases the Growth Direct System; an RMM (Rapid Microbial Method) that improves on traditional membrane filtration, delivering increased accuracy, a faster time to result, enhanced data integrity compliance, and more control over the manufacturing process.

Key learning points:

  • Understand the benefits of full workflow microbiology quality control testing automation in radiopharmaceutical production
  • Learn about ITM’s implementation journey and considerations when evaluating the technology
  • Find out how the advanced optics and microcolony detection capabilities of Growth Direct® technology impact time to result (TTR).

Don’t miss your chance to learn from experts in the industry – Register for FREE

 

The presentation will discuss the decision making process, methodology, competitive advantages, strategic implementation and challenges related to adapting and transitioning to a single use manufacturing system versus a fixed stainless steel system. In addition, the presentation will provide an update on the building process and highlight the theoretical business case versus the reality of implementation.

Catalent helps customers achieve competitive advantage by producing stable, high-yielding mammalian cell lines, and by providing robust bio-manufacturing services with industry leading timelines.

Dr. Michael Jenkins has been with Catalent Pharma Solutions for more than nine years. Before becoming General Manager of Catalent’s Middleton, WI facility, he held senior roles in Commercial Operations and as Vice President of Business Development. Dr. Jenkins has previous industry experience in the development of mammalian cell culture and has also held technical roles at a plant transgenics company. He was awarded his Ph.D. by the Department of Molecular and Cellular Biology at the University of Arizona, with a minor in Biochemistry and has a B.S. in Microbiology from the University of Illinois at Champaign Urbana. Dr. Jenkins’ areas of interest include traditional and transgenic biologics manufacturing platforms, the evaluation and establishment of innovative technologies in the biotechnology marketplace and where these interests merge to reduce the cost of developing and manufacturing products.

For more information on the 2012 Bio-Process Systems Alliance (BPSA) International Single-Use Summit, please visit http://www.bpsalliance.org/summit.html.

Related topics

Related organisations